STOCK TITAN

Medicure Inc - MCUJF STOCK NEWS

Welcome to our dedicated news page for Medicure (Ticker: MCUJF), a resource for investors and traders seeking the latest updates and insights on Medicure.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Medicure's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Medicure's position in the market.

Rhea-AI Summary
Medicure Inc. receives US FDA Fast Track Designation for MC-1 to treat seizures associated with PNPO Deficiency. The company's Phase 3 clinical trial is underway to address this rare neurometabolic disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.54%
Tags
-
Rhea-AI Summary
Medicure Inc. reports financial results for the quarter and year ended December 31, 2023. Total net revenue was $21.7 million for the year and $5.1 million for the quarter. Revenue from AGGRASTAT decreased, while revenue from ZYPITAMAG and Marley Drug increased. Adjusted EBITDA was $1.9 million, with a net loss of $922,000 for the year. Cash reserves increased to $6.4 million. The Company plans an investor conference call in May 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Medicure Inc. will present its 2023 Year End Financial Results on April 9, 2024, focusing on pharmaceuticals and healthcare products for the US market. The conference call will provide insights into the company's financial performance and operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Summary
Medicure Inc. (TSXV:MPH)(OTC PINK:MCUJF) partners with TheracosBio to distribute BRENZAVVY, a newly approved diabetes drug, at an affordable cash price, aiming to improve patient care and well-being in the US market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
Rhea-AI Summary
Medicure Inc. (MPH) Receives FDA Approval for Phase 3 Clinical Trial of MC-1 for Rare Pediatric Disease PNPO Deficiency
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.65%
Tags
-
Rhea-AI Summary
Medicure Inc. (MPH) reported its results from operations for the quarter ended September 30, 2023, with total net revenue of $5.0 million. The company recorded a decrease in AGGRASTAT® and ZYPITAMAG® sales compared to the same quarter in 2022, resulting in an adjusted EBITDA of $429,000 and a net income of $84,000. The company remains cash flow positive with unrestricted cash totaling $5.6 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Medicure Inc. reaffirms commitment to providing affordable access to pitavastatin (ZYPITAMAG) for people living with HIV
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Medicure Inc. (MPH) reported its Q2 2023 financial results, with a total net revenue of $6.0 million, a record net income of $253,000, and unrestricted cash totaling $5.4 million. The revenue from AGGRASTAT® and ZYPITAMAG® showed a modest decrease, while Marley Drug business contributed significantly to the total net revenue. The adjusted EBITDA for the quarter ended June 30, 2023, was $948,000, representing a substantial increase from the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.77%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Medicure Inc

OTC:MCUJF

MCUJF Rankings

MCUJF Stock Data

8.29M
5.26M
26.99%
23.1%
0.17%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Canada
Winnipeg